FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973195462> ?p ?o ?g. }

• W2973195462 endingPage "1363" @default.
• W2973195462 startingPage "1353" @default.
• W2973195462 abstract "Abstract Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single‐agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high‐risk features. Here we report the final analysis from RESONATE with median follow‐up on study of 65.3 months (range, 0.3‐71.6) in the ibrutinib arm. Median progression‐free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113‐0.196; P ˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418‐0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all‐grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long‐term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high‐risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707)." @default.
• W2973195462 created "2019-09-19" @default.
• W2973195462 creator A5000921376 @default.
• W2973195462 creator A5006104041 @default.
• W2973195462 creator A5007254355 @default.
• W2973195462 creator A5008204241 @default.
• W2973195462 creator A5014241029 @default.
• W2973195462 creator A5016570475 @default.
• W2973195462 creator A5034517642 @default.
• W2973195462 creator A5036828560 @default.
• W2973195462 creator A5036988600 @default.
• W2973195462 creator A5039819830 @default.
• W2973195462 creator A5041332488 @default.
• W2973195462 creator A5047631289 @default.
• W2973195462 creator A5048416913 @default.
• W2973195462 creator A5055100327 @default.
• W2973195462 creator A5056554686 @default.
• W2973195462 creator A5058755419 @default.
• W2973195462 creator A5068134700 @default.
• W2973195462 creator A5085325467 @default.
• W2973195462 creator A5087985272 @default.
• W2973195462 creator A5089625305 @default.
• W2973195462 date "2019-10-13" @default.
• W2973195462 modified "2023-10-12" @default.
• W2973195462 title "Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma" @default.
• W2973195462 cites W1243376384 @default.
• W2973195462 cites W1429374962 @default.
• W2973195462 cites W1992857313 @default.
• W2973195462 cites W2009009231 @default.
• W2973195462 cites W2071549499 @default.
• W2973195462 cites W2108206643 @default.
• W2973195462 cites W2116835043 @default.
• W2973195462 cites W2120319857 @default.
• W2973195462 cites W2125134816 @default.
• W2973195462 cites W2140606816 @default.
• W2973195462 cites W2142099365 @default.
• W2973195462 cites W2144617723 @default.
• W2973195462 cites W2149515595 @default.
• W2973195462 cites W2151177887 @default.
• W2973195462 cites W2163690533 @default.
• W2973195462 cites W2271365036 @default.
• W2973195462 cites W2295348655 @default.
• W2973195462 cites W2316021978 @default.
• W2973195462 cites W2318933236 @default.
• W2973195462 cites W2369297677 @default.
• W2973195462 cites W2461753455 @default.
• W2973195462 cites W2550091596 @default.
• W2973195462 cites W2621465594 @default.
• W2973195462 cites W2621758445 @default.
• W2973195462 cites W2623762297 @default.
• W2973195462 cites W2739393823 @default.
• W2973195462 cites W2744781811 @default.
• W2973195462 cites W2773047201 @default.
• W2973195462 cites W2787863642 @default.
• W2973195462 cites W2790385276 @default.
• W2973195462 cites W2790448887 @default.
• W2973195462 cites W2799716396 @default.
• W2973195462 cites W2897636215 @default.
• W2973195462 cites W2945468305 @default.
• W2973195462 cites W4251009301 @default.
• W2973195462 doi "https://doi.org/10.1002/ajh.25638" @default.
• W2973195462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6899718" @default.
• W2973195462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31512258" @default.
• W2973195462 hasPublicationYear "2019" @default.
• W2973195462 type Work @default.
• W2973195462 sameAs 2973195462 @default.
• W2973195462 citedByCount "265" @default.
• W2973195462 countsByYear W29731954622019 @default.
• W2973195462 countsByYear W29731954622020 @default.
• W2973195462 countsByYear W29731954622021 @default.
• W2973195462 countsByYear W29731954622022 @default.
• W2973195462 countsByYear W29731954622023 @default.
• W2973195462 crossrefType "journal-article" @default.
• W2973195462 hasAuthorship W2973195462A5000921376 @default.
• W2973195462 hasAuthorship W2973195462A5006104041 @default.
• W2973195462 hasAuthorship W2973195462A5007254355 @default.
• W2973195462 hasAuthorship W2973195462A5008204241 @default.
• W2973195462 hasAuthorship W2973195462A5014241029 @default.
• W2973195462 hasAuthorship W2973195462A5016570475 @default.
• W2973195462 hasAuthorship W2973195462A5034517642 @default.
• W2973195462 hasAuthorship W2973195462A5036828560 @default.
• W2973195462 hasAuthorship W2973195462A5036988600 @default.
• W2973195462 hasAuthorship W2973195462A5039819830 @default.
• W2973195462 hasAuthorship W2973195462A5041332488 @default.
• W2973195462 hasAuthorship W2973195462A5047631289 @default.
• W2973195462 hasAuthorship W2973195462A5048416913 @default.
• W2973195462 hasAuthorship W2973195462A5055100327 @default.
• W2973195462 hasAuthorship W2973195462A5056554686 @default.
• W2973195462 hasAuthorship W2973195462A5058755419 @default.
• W2973195462 hasAuthorship W2973195462A5068134700 @default.
• W2973195462 hasAuthorship W2973195462A5085325467 @default.
• W2973195462 hasAuthorship W2973195462A5087985272 @default.
• W2973195462 hasAuthorship W2973195462A5089625305 @default.
• W2973195462 hasBestOaLocation W29731954621 @default.
• W2973195462 hasConcept C126322002 @default.
• W2973195462 hasConcept C143998085 @default.
• W2973195462 hasConcept C207103383 @default.
• W2973195462 hasConcept C2777609679 @default.

• next